TY - JOUR
T1 - Safety of vedolizumab in liver transplant recipients
T2 - A systematic review
AU - Spadaccini, Marco
AU - Aghemo, Alessio
AU - Caprioli, Flavio
AU - Lleo, Ana
AU - Invernizzi, Federica
AU - Danese, Silvio
AU - Donato, Maria F.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Background: The management of inflammatory bowel disease in patients who have previously undergone liver transplantation can be a clinical challenge. There are serious concerns among physicians regarding the use of biologics for treating such immuno-compromised patients. Objective: We performed a systematic review on vedolizumab therapy in transplant recipients to assess its safety. Methods: PubMed/Embase/Scopus were searched up to November 2018 to identify papers regarding liver transplant recipients and therapy with vedolizumab. Primary outcomes were adverse events. Secondary outcomes were liver transplant and inflammatory bowel disease outcomes. Results: Eight studies (31 patients) were included. Nine out of 31 patients experienced an infection within a mean follow-up time ranging from 5–20 months. No malignancies were reported. Inflammatory bowel disease clinical response was experienced by 20/26 patients. Abnormalities in liver tests were recorded in 2/22 patients. Conclusion: Vedolizumab may be considered safe for treating inflammatory bowel disease in liver transplant recipients. Caution is recommended for patients with an unstable liver graft function.
AB - Background: The management of inflammatory bowel disease in patients who have previously undergone liver transplantation can be a clinical challenge. There are serious concerns among physicians regarding the use of biologics for treating such immuno-compromised patients. Objective: We performed a systematic review on vedolizumab therapy in transplant recipients to assess its safety. Methods: PubMed/Embase/Scopus were searched up to November 2018 to identify papers regarding liver transplant recipients and therapy with vedolizumab. Primary outcomes were adverse events. Secondary outcomes were liver transplant and inflammatory bowel disease outcomes. Results: Eight studies (31 patients) were included. Nine out of 31 patients experienced an infection within a mean follow-up time ranging from 5–20 months. No malignancies were reported. Inflammatory bowel disease clinical response was experienced by 20/26 patients. Abnormalities in liver tests were recorded in 2/22 patients. Conclusion: Vedolizumab may be considered safe for treating inflammatory bowel disease in liver transplant recipients. Caution is recommended for patients with an unstable liver graft function.
KW - adverse events
KW - inflammatory bowel disease
KW - Liver transplantation
KW - primary sclerosing cholangitis
KW - vedolizumab
UR - http://www.scopus.com/inward/record.url?scp=85068161201&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068161201&partnerID=8YFLogxK
U2 - 10.1177/2050640619858050
DO - 10.1177/2050640619858050
M3 - Review article
AN - SCOPUS:85068161201
SN - 2050-6406
VL - 7
SP - 875
EP - 880
JO - United European Gastroenterology Journal
JF - United European Gastroenterology Journal
IS - 7
ER -